Weill Cornell Medicine Oncology & Hematology

 

Weill Cornell Medicine Oncology & Hematology
Avatar

ITP Receptor Agonists Efficacy Analysis: Romiplostim, Eltrombopag and Avatrombopag - How Do They Work and When Should We Use Them? What Is the Optimal Dosing? What About Discontinuation and Side Effects?

By Weill Cornell Medicine Oncology & Hematology FEATURING James Bussel
By Weill Cornell Medicine Oncology & Hematology FEATURING James Bussel
0 views
September 29, 2020
Comments 0
Login to view comments. Click here to Login
Videos
22:07
Weill Cornell Medicine Oncology & Hematology

Urothelial Carcinoma: New Developments

Feat. C. Sternberg
19:17
Weill Cornell Medicine Oncology & Hematology

Inflammatory Breast Cancer - Diagnosis and Management Updates

Feat. M. Cristofanilli
11:23
Weill Cornell Medicine Oncology & Hematology

ASCO® GI 2024 Insights: "The NEST-1 Trial - Neoadjuvant BOT/BAL…

Feat. P. Kasi
31:28
Weill Cornell Medicine Oncology & Hematology

Year in Review: ctDNA in Colorectal Cancer

Feat. P. Kasi
08:59
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "SWOG S1826 Trial - Nivo-AVD vs. Bv-AVD in O…

Feat. S. Rutherford
13:16
Weill Cornell Medicine Oncology & Hematology

Monitoring Response to Therapy in mCRPC: What Parameters to Look at

Feat. D. Nanus
23:38
Weill Cornell Medicine Oncology & Hematology

Radiation Combined With IO for the Treatment of SCLC

Feat. A. Saxena
08:25
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Phase I Dose-Escalation Results of PSMA-T…

Feat. S. Tagawa
08:22
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Efficacy and Safety Analysis of Sacituzum…

Feat. S. Tagawa
05:18
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "PSMAddition - A Phase 3 Trial to Compare …

Feat. S. Tagawa
07:15
Weill Cornell Medicine Oncology & Hematology

Eltrombopag in ITP: Learnings From the RAISE and EXTEND Trials

Feat. J. Bussel
04:49
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Updated Outcomes in TROPHY-U-01 Cohort 1-A Phase 2 Stud…

Feat. S. Tagawa
05:48
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Randomized Double-Blinded Phase II Study of Keto HC and…

Feat. S. Tagawa
12:05
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Novel Guidelines for PSMA PET Staging of Prostate Cance…

Feat. D. Nanus
29:05
Indy Hematology Review

Aggressive Lymphoma - Nursing and Allied Providers Symposium

Feat. J. Leonard
27:15
Indy Hematology Review

Aggressive B-Cell and T-Cell Lymphomas: Emerging Therapies

Feat. J. Leonard
02:29
Weill Cornell Medicine Oncology & Hematology

CLONEVO: Cell Cycle Inhibition to Target the Evolution of Urothelial…

Feat. B. Faltas
12:11
Weill Cornell Medicine Oncology & Hematology

Pain Management in Sickle Cell Disease

Feat. S. Jain, J. Bussel
11:30
ASCO 2022 Conference Coverage

ASCO 2022 Expert Discussion: Current Treatment Approaches in Hemophi…

Feat. J. Bussel, C. Mcguinn
09:13
Weill Cornell Medicine Oncology & Hematology

Eltrombopag for the Treatment of Children With Persistent and Chroni…

Feat. J. Bussel
10:29
ASCO 2022 Conference Coverage

ASCO 2022 Using cfDNA to Identify Guideline-Relevant Biomarkers for …

Feat. P. Kasi
06:24
Weill Cornell Medicine Oncology & Hematology

SYK Inhibitors for the Treatment of ITP

Feat. J. Bussel
09:29
i3 Health

Updates in Mantle Cell Lymphoma

Feat. J. Leonard
13:17
ASCO Genitourinary Cancers Symposium

ASCO GU 2022 Highlights on the ADCs in Advanced Urothelial Cancer: C…

Feat. S. Tagawa
12:29
ASH 2021 Conference Coverage on VuMedi

ASH 2021 on Older Patients With AML: So I Am in Remission - Now What?

Feat. P. Desai
09:55
ASH 2021 Conference Coverage on VuMedi

ASH 2021: Comparing Outcomes Between CPX-351 and HMA+Ven As 1L Thera…

Feat. P. Desai
08:38
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Clinical Predictors of Outcomes in Adult Acute Leukemias an…

Feat. P. Desai
10:27
Richard T. Silver

Splenomegaly in Polycythemia Vera: Clinical Significance and Relatio…

21:36
2021 International Congress on Myeloproliferative Neoplasms

MPN Stem Cell Fitness and the Link to Clinical Outcomes

Feat. J. Scandura
15:12
2021 International Congress on Myeloproliferative Neoplasms

A Novel Machine Learning-Derived Dynamic Scoring System Predicts Ris…

Feat. G. Abu-Zeinah
12:42
2021 International Congress on Myeloproliferative Neoplasms

Pediatric MPNs: An Unfamiliar Topic

Feat. N. Kucine
08:40
Weill Cornell Medicine Oncology & Hematology

WCLC 2021 Data From IMpower010: Characterization of Stage IB-IIIA NS…

Feat. N. Altorki
10:41
ecancer

EHA 2021 Update on 1L Ibrutinib + Venetoclax for CLL/SLL: Primary An…

Feat. J. Allan
12:23
Weill Cornell Medicine Oncology & Hematology

Evaluating mCRPC Using 177LU-PNT2002 PSMA Therapy After 2L Hormonal …

Feat. S. Tagawa
11:45
Weill Cornell Medicine Oncology & Hematology

ASCO 2021 Data on PSMA-Targeted Alpha Emitter 225Ac-J591 in Men With…

Feat. S. Tagawa
08:16
Weill Cornell Medicine Oncology & Hematology

Newly FDA-Approved Sacituzumab Govitecan for Advanced Urothelial Car…

Feat. S. Tagawa
15:35
3rd Annual Hematologic Malignancies Symposium

How I Treat Elderly AML Patients in 2021: Does Midostaurin Improve O…

Feat. G. Roboz
09:40
Weill Cornell Medicine Oncology & Hematology

Key Symptoms and HRQoL in Chronic ITP: How Much Does ITP Affect QoL?…

Feat. J. Bussel
12:29
2nd SOHO Italian Conference

Managing Hodgkin Lymphoma: PET Adapted Strategies, Applying ECHELON-…

Feat. J. Leonard
19:44
2nd SOHO Italian Conference

How I Treat DLBCL in 2020: Who Shouldn't Get Standard Treatment…

Feat. .
18:23
Weill Cornell Medicine Oncology & Hematology

2020 Update on TPO Agents: How Effective Are They in Chemotherapy-In…

Feat. J. Bussel
17:03
Weill Cornell Medicine Oncology & Hematology

ITP Receptor Agonists Efficacy Analysis: Romiplostim, Eltrombopag an…

Feat. J. Bussel
20:28
University of Miami's 2nd Biennial Miami Leukemia Symposium

Tailoring Therapies to Target Leukemia Stem Cells: PU-FITC Binding A…

Feat. M. Guzman
18:43
PeerView Oncology

Management of R/R MCL: Ibrutinib and Acalabrutinib Data, Venetoclax …

Feat. J. Ruan
08:56
PeerView Oncology

Management of R/R MCL: Lenalidomide w/ Rituximab & CAR T Therapy

Feat. J. Ruan
21:24
Weill Cornell Medicine Oncology & Hematology

Treatment Options for Older and Elderly Patients With AML: How to Us…

Feat. P. Desai
19:58
12th International Congress on Myeloproliferative Neoplasms

How Should We Treat Children w/ MPN: No Guidelines on Cytoreduction …

Feat. N. Kucine
17:00
12th International Congress on Myeloproliferative Neoplasms

Interferon in Polycythemia Vera (PV) Yields Improved Myelofibrosis-F…

Feat. R. Silver
28:30
12th International Congress on Myeloproliferative Neoplasms

Is There a Role of Transplantation for CML in the Era of TKIs?

Feat. K. Van Besien
22:37
ESO Lymphoma Course

Common "Epigenetic" Somatic Mutations in Lymphoma: CREBBP,…

Feat. A. Melnick
33:55
ESO Lymphoma Course

Pathogenesis of Mature B-Cell Lymphomas: Germinal Center‐derived Lym…

Feat. A. Melnick
40:14
UNMC Leukemia Symposium: Focus on Opportunities to Improve Care

Novel Treatment Options for AML and Overview of Related Trials - Mov…

Feat. G. Roboz
16:17
Indy Hematology Review

Treatment and New Trials in DLBCL - Modifications to R-CHOP Based on…

Feat. J. Leonard
11:24
Indy Hematology Review

Brentuximab Vedotin for Previously Untreated Peripheral T-cell Lymph…

Feat. J. Leonard
05:14
Indy Hematology Review

Axi cell CAR T-cell Therapy for Refractory DLBCL - Overview of ZUMA-…

Feat. J. Leonard